Press Releases

Date	Title and Summary	Additional Formats
Toggle SummaryOct 31, 2017	Xencor to Host Third Quarter 2017 Financial Results Webcast and Conference Call on November 7, 2017 MONROVIA, Calif. , Oct. 31, 2017 /PRNewswire/ -- Xencor , Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune diseases, asthma and allergic diseases and cancer, announced that it will release third quarter 2017	View HTML Xencor to Host Third Quarter 2017 Financial Results Webcast and Conference Call on November 7, 2017 30.8 KB
Toggle SummaryOct 20, 2017	Xencor to Present Final Results from Phase 2 Study of XmAb®5871 in IgG4-Related Disease at American College of Rheumatology (ACR) 2017 Annual Meeting -- Accepted for Late-Breaking Abstract Session --	View HTML Xencor to Present Final Results from Phase 2 Study of XmAb®5871 in IgG4-Related Disease at American College of Rheumatology (ACR) 2017 Annual Meeting 90.8 KB
Toggle SummarySep 20, 2017	Xencor to Present at Upcoming Investor Conferences MONROVIA, Calif. , Sept. 20, 2017 /PRNewswire/ -- Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune diseases, asthma and allergic diseases and cancer, today announced that company management will	View HTML Xencor to Present at Upcoming Investor Conferences 33.3 KB
Toggle SummaryAug 07, 2017	Xencor Reports Second Quarter 2017 Financial Results -- Management to Host Conference Call Today at 4:30 p.m. ET --	View HTML Xencor Reports Second Quarter 2017 Financial Results 57.3 KB
Toggle SummaryAug 02, 2017	Xencor to Present at Upcoming Investor Conferences MONROVIA, Calif. , Aug. 2, 2017 /PRNewswire/ -- Xencor , Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune diseases, asthma and allergic diseases and cancer, today announced that company management will	View HTML Xencor to Present at Upcoming Investor Conferences 33.3 KB
Toggle SummaryJul 31, 2017	Xencor to Host Second Quarter 2017 Financial Results Webcast and Conference Call on August 7, 2017 MONROVIA, Calif. , July 31, 2017 /PRNewswire/ -- Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune diseases, asthma and allergic diseases and cancer, announced that it will release second quarter	View HTML Xencor to Host Second Quarter 2017 Financial Results Webcast and Conference Call on August 7, 2017 30.8 KB
Toggle SummaryJun 16, 2017	Xencor Presents Interim Data from an Ongoing, Open-label, Phase 2 Study of XmAb®5871 in IgG4-Related Disease at EULAR 2017 - 14 of 15 patients (93%) achieved a response to therapy, 12 of them within 2 weeks of first dose -- 6 patients attained disease remission (an IgG4-RD Responder Index of 0) -- Every other week intravenous administration of XmAb5871 in patients with active IgG4-RD has been well tolerated -	View HTML Xencor Presents Interim Data from an Ongoing, Open-label, Phase 2 Study of XmAb®5871 in IgG4-Related Disease at EULAR 2017 92.6 KB
Toggle SummaryJun 08, 2017	Xencor Appoints Raphael Clynes, M.D., Ph.D., as Vice President of Translational Biology MONROVIA, Calif. , June 8, 2017 /PRNewswire/ -- Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune diseases, asthma and allergic diseases, and cancer, today announced the appointment of Raphael Clynes	View HTML Xencor Appoints Raphael Clynes, M.D., Ph.D., as Vice President of Translational Biology 32.3 KB
Toggle SummaryMay 30, 2017	Xencor to Present at Jefferies 2017 Global Healthcare Conference MONROVIA, Calif. , May 30, 2017 /PRNewswire/ -- Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune diseases, asthma and allergic diseases and cancer, today announced that Bassil Dahiyat, Ph.D.,	View HTML Xencor to Present at Jefferies 2017 Global Healthcare Conference 26.9 KB
Toggle SummaryMay 11, 2017	Xencor's Lead Drug Candidate, XmAb5871, Receives Orphan Drug Designation from FDA for Treatment of IgG4-Related Disease MONROVIA, Calif. , May 11, 2017 /PRNewswire/ -- Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune diseases, asthma and allergic diseases and cancer, announced today that XmAb®5871 has been granted	View HTML Xencor's Lead Drug Candidate, XmAb5871, Receives Orphan Drug Designation from FDA for Treatment of IgG4-Related Disease 85.7 KB

Tools

Press Releases